Sei Investments Co. Trims Holdings in argenex SE $ARGX

Sei Investments Co. decreased its holdings in shares of argenex SE (NASDAQ:ARGX) by 1.3% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 312,268 shares of the company’s stock after selling 4,131 shares during the period. Sei Investments Co.’s holdings in argenex were worth $230,318,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also bought and sold shares of ARGX. Ameriflex Group Inc. purchased a new position in shares of argenex during the third quarter valued at approximately $32,000. Bessemer Group Inc. lifted its stake in argenex by 276.5% in the third quarter. Bessemer Group Inc. now owns 64 shares of the company’s stock worth $47,000 after acquiring an additional 47 shares during the period. MAI Capital Management lifted its stake in argenex by 866.7% in the second quarter. MAI Capital Management now owns 87 shares of the company’s stock worth $48,000 after acquiring an additional 78 shares during the period. Mather Group LLC. bought a new stake in argenex in the third quarter valued at $50,000. Finally, Rossby Financial LCC boosted its holdings in argenex by 115.2% in the third quarter. Rossby Financial LCC now owns 71 shares of the company’s stock valued at $54,000 after acquiring an additional 38 shares in the last quarter. Hedge funds and other institutional investors own 60.32% of the company’s stock.

Analysts Set New Price Targets

Several research analysts have commented on the stock. Guggenheim decreased their price objective on shares of argenex from $1,160.00 to $1,120.00 and set a “buy” rating for the company in a report on Friday, February 27th. Truist Financial lifted their target price on shares of argenex from $950.00 to $1,030.00 and gave the company a “buy” rating in a research note on Thursday, January 8th. Wedbush reiterated an “outperform” rating and set a $1,000.00 price target on shares of argenex in a research report on Monday. Robert W. Baird increased their price target on shares of argenex from $858.00 to $867.00 and gave the stock a “neutral” rating in a research note on Friday, February 27th. Finally, Wall Street Zen lowered shares of argenex from a “buy” rating to a “hold” rating in a report on Sunday, March 8th. One investment analyst has rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and four have issued a Hold rating to the company. Based on data from MarketBeat, argenex presently has a consensus rating of “Moderate Buy” and an average price target of $999.22.

argenex Price Performance

NASDAQ:ARGX opened at $708.85 on Friday. The firm’s 50-day moving average price is $806.79 and its 200-day moving average price is $815.81. The company has a market capitalization of $43.86 billion, a PE ratio of 36.31, a P/E/G ratio of 1.20 and a beta of 0.38. argenex SE has a 1-year low of $510.05 and a 1-year high of $934.62.

argenex (NASDAQ:ARGX) last issued its quarterly earnings results on Thursday, February 26th. The company reported $8.02 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $6.05 by $1.97. argenex had a net margin of 30.42% and a return on equity of 38.51%. The company had revenue of $1.32 billion during the quarter, compared to analysts’ expectations of $1.30 billion. Equities analysts anticipate that argenex SE will post 3.13 EPS for the current fiscal year.

About argenex

argenx (NASDAQ: ARGX) is a biotechnology company focused on the discovery, development and commercialization of antibody-based therapeutics for severe autoimmune and neuromuscular diseases. The company uses its proprietary SIMPLE Antibody platform to generate differentiated antibodies and engineered Fc regions, and it pursues mechanisms that modulate the neonatal Fc receptor (FcRn) to reduce pathogenic IgG levels. Argenx’s research and development activities span target identification, preclinical development and late-stage clinical programs aimed at addressing unmet needs in immunology.

The company’s lead product, efgartigimod (marketed as Vyvgart), is an FcRn antagonist developed to reduce circulating IgG antibodies and treat IgG-mediated disorders.